Bemotrizinol is a newly approved over-the-counter sunscreen active ingredient that offers broad-spectrum protection with low systemic absorption.
The phase 3 KEYNOTE-D46/EVOKE-03 study evaluated sacituzumab govitecan/pembrolizumab vs pembrolizumab in untreated PD-L1-high metastatic NSCLC.
Phase 3 ISLEND-1 and ISLEND-2 trials met primary endpoints at week 48, showing a novel, once-weekly oral single-tablet regimen is noninferior to daily B/F/TAF or standard ART.
For adults with type 2 diabetes receiving guideline-directed renin-angiotensin inhibitors (RASi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), dihydropyridine calcium-channel-blocker (DCCB) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results